Advance on the central serous chorioretinopathy

doi:10.3877/cma.j.issn.2095-2007.2025.02.010

Abstract

Abstract:

Central serous chorioretinopathy（CSC）is characterized by localized，serous retinal detachment，most affect at the macular，usually associated with pigment epithelial detachments（PED），retinal pigment epithelial（rPE）dysfunction，and choroidal thickening，hyperpermeability and venous overload.The etiological mechanism and pathogenesis of CSC are not yet completely understood，but choroidal lesions and RPEdysfunction are integral to its entire pathological progression.The treatment always focuses on resolving the retinal detachment，but choroid lesions in CSC are still in difficulties.The progress of choroid disease in CSC was reviewed in this paper.

Key words: Central serous chorioretinopathy, Retinal pigment epithelium, Pachychoroid disease, Choroid diseases

Jinbo Wang, Zhaoxia Zhang, Bin Sun. Advance on the central serous chorioretinopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2025, 15(02): 119-123.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2025.02.010

https://zhykyxzz.cma-cmc.com.cn/EN/Y2025/V15/I02/119

Figures/Tables 1

References 58

［1］	Çiloĝlu E，Unal F，Dogan NC.The relationship between the central serous chorioretinopathy，choroidal thickness，and serum hormone levels［J］.Graefes Arch Clin Exp Ophthalmol，2018，256（6）：1111-1116.
［2］	Fung AT，Yang Y，Kam AW.Central serous chorioretinopathy：A review［J］.Clin Exp Ophthalmol，2023，51（3）：243-270.
［3］	Tsai DC，Chen SJ，Huang CC，et al.Epidemiology of idiopathic central serous chorioretinopathy in Taiwan， 2001-2006： a population-based study［J］.PloSOne，2013，8（6）：1-7.
［4］	Mehta PH，Chhablani J， Wang J， et al. Central serous chorioretinopathy in African Americans at Wilmer eye institute［J］.J Natl Med Assoc，2018，110（3）：297-302.
［5］	Pan CK，Vail D，Bhattacharya J，et al.The effect of obstructive sleep apnea on absolute risk of central serous chorioretinopathy［J］.Am JOphthalmol，2020，218：148-155.
［6］	李建军，张风.中心性浆液性脉络膜视网膜病变的治疗进展［J］.眼科，2011，20（6）：230-234.
［7］	Chhablani J，Cohen FB.Multimodal imaging-based central serous chorioretinopathy classification［J］.Ophthalmol Retina，2020，4（11）：1043-1046.
［8］	徐丽，王治骞，庄晓彤.中心性浆液性脉络膜视网膜病变研究近况及治疗［J］.中国实用眼科杂志，2017，35（6）：553-557.
［9］	Irini C. Risk factors for central serous chorioretinopathy：Multivariate approach in a case-control study［J］.Curr Eye Res，2017，42（7）：1069-1073.
［10］	Youngsub E.Systemic factors associated with central serous chorioretinopathy in Koreans［J］.Korean J Ophthalmol，2012，26（4）：260-264.
［11］	Singh SR，Dogra M，Dogra MR，et al.Dark spot in fibrinous central serous chorioretinopathy［J］.JAMA Ophthalmol，2018，21（3）：201-206.
［12］	Rijssen TJV，Dijk EHCV，Yzer S， et al. Central serous chorioretinopathy：Towards an evidence-based treatment guideline［J］.Prog Retin Eye Res，2019，73：100770.
［13］	Hanumunthadu D，Tan ACS，Singh SR，et al.Management of chronic central serous chorioretinopathy［J］. Indian J Ophthalmol，2017，66（12）：1704-1714.
［14］	Sugiura A，Fujino R，Takemiya N，et al.The association between visual function and retinal structure in chronic central serous chorioretinopathy［J］.Sci Rep，2017，7（1）：16288.
［15］	Guyer DR，Yannuzzi LA，Slakter JS，et al.Digital indocyanine green videoangiography of central serous chorioretinopathy［J］.Arch Ophthalmol，1994，112（8）：1057-1062.
［16］	Piccolino FC，Borgia L.Central serous chorioretinopathy and indocyanine green angiography［J］.Retina，1994，14（3）：231-242.
［17］	Prünte C.Indocyanine green angiographic findings in central serous chorioretinopathy［J］.Int Ophthalmol，1995，19：77-82.
［18］	Kitaya N，Nagaoka T，Hikichi T，et al.Features of abnormal choroidal circulation in central serous chorioretinopathy［J］.Br J Ophthalmol，2003，87（6）：709-712.
［19］	Kaye RA，Peto T，Hogg R，et al.Choroidal vascularity in chronic central serous chorioretinopathy and its association with risk single-nucleotide polymorphisms［J］.Retina，2022，44（5）：837-843.
［20］	Kaye R， Chandra S， Sheth J， et al. Central serous chorioretinopathy：An update on risk factors，pathophysiology and imaging modalities［J］.Prog Retin Eye Res，2020，79：100865.
［21］	Lee M，Lee H，Kim HC，et al.Changes in stromal and luminal areas of the choroid in pachychoroid diseases：insights into the pathophysiology of pachychoroid diseases［J］.Invest Ophthalmol Vis Sci，2018，59（12）：4896-4908.
［22］	Schubert C，Pryds A，Zeng S，et al.Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy［J］.Hum Mutat，2014，35（7）：859-867.
［23］	Yang HS，Kang TG，Park H，et al.Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy［J］.PLoS One，2020，15（1）：e0227718.
［24］	Maruko I，Iida T，Sugano Y，et al.Subfoveal choroidal thickness after treatment of central serous chorioretinopathy［J］.Ophthalmology，2010，117（9）：1792-1799.
［25］	Feenstra HM，Van-Dijk EH，Cheung CMG，et al.Central serous chorioretinopathy：An evidence-based treatment guideline［J］.Prog Retin Eye Res，2024，101：101236.
［26］	He G，Zhang X，Gan Y，et al.Choroidal vein alterations in pachychoroid disease with choroidal vascular hyperpermeability：Evaluated by wide-field indocyanine green angiography［J］.Invest Ophthalmol Vis Sci，2023，64（11）：25.
［27］	Warrow DJ，Hoang QV，Freund KB.Pachychoroid pigment epitheliopathy［J］.Retina，2013，33（8）：1659-1672.
［28］	Zhang X，Sivaprasad S.Drusen and pachydrusen：the definition，pathogenesis，and clinical significance［J］.Eye，2021，35（1）：121-133.
［29］	Cheung CMG，Lee WK，Koizumi H，et al.Pachychoroid disease［J］.Eye，2018，33（1）：14-33.
［30］	Dansingani KK，Balaratnasingam C，Naysan J，et al.En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography［J］.Retina，2016，36（3）：499-516.
［31］	Baek J，Lee JH，Jung BJ，et al.Morphologic features of large choroidal vessel layer： age-related macular degeneration，polypoidal choroidal vasculopathy， and central serous chorioretinopathy［J］.Graefes Arch Clin Exp Ophthalmol，2018，256：2309-2317.
［32］	Yamashiro K，Hosoda Y，Miyake M，et al.Characteristics of pachychoroid diseases and age-related macular degeneration：Multimodal imaging and genetic backgrounds［J］.J Clin Med，2020，9（7）：2034.
［33］	Moraru AD，Costin D，Moraru RL，et al.Current diagnosis and management strategies in pachychoroid spectrum of diseases（review）［J］.Exp Ther Med，2020，20（4）：3528-3535.
［34］	Matsumoto H，Kishi S，Mukai R，et al.Remodeling of macular vortex veins in pachychoroid neovasculopathy［J］.Sci Rep，2019，9（1）：14689.
［35］	沈静，谢兵.肥厚型脉络膜谱系疾病的研究进展［J］.国际眼科杂志，2021，21（8）：1399-1403.
［36］	Manayath GJ，Shah VS，Saravanan VR，et al.Polypoidal choroidal vasculopathy associated with central serous chorioretinopathy：Pachychoroid spectrum of diseases［J］.Retina，2018，38（6）：1195-1204.
［37］	李璐希，张鹏.肥厚型脉络膜疾病谱的研究进展［J］.中华眼科杂志，2023，59（1）：68-72.
［38］	Yang S，Zhou J，Li DW.Functions and diseases of the retinal pigment epithelium［J］.Front Pharmacol，2021，12：72870.
［39］	Sagar P，Sodhi PS，Roy S，et al.Pachychoroid neovasculopathy：A comparative review on pathology，clinical features，and therapy［J］.Eur JOphthalmol，2021，PMID：34325545.
［40］	Sato T，Kishi S，Watanabe G，et al.Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy［J］.Retina，2007，27（5）：589-594.
［41］	Borooah S，Sim PY，Phatak S，et al.Pachychoroid spectrum disease［J］.Acta Ophthalmol，2021，99（6）：e806-e822.
［42］	Kanda P，Gupta A，Gottlieb C，et al.Pathophysiology of central serous chorioretinopathy： A literature review with quality assessment［J］.Eye，2022，36（5）：941-962.
［43］	Spitznas M.Pathogenesis of central serous retinopathy：a new working hypothesis［J］.Graefes Arch Clin Exp Ophthalmol，1986，224：321-324.
［44］	林慧敏，张静琳.中心性浆液性脉络膜视网膜病变的发病机制及诊疗进展［J］.国际眼科纵览，2019，43（3）：166-169.
［45］	Gemenetzi M， De-Salvo G， Lotery AJ. Central serous chorioretinopathy：an update on pathogenesis and treatment［J］.Eye，2010，24（12）：1743-1756.
［46］	Newman DK.Photodynamic therapy：current role in the treatment of chorioretinal conditions［J］.Eye，2016，30（2）：202-210.
［47］	Feenstra HMA，Diederen RMH，Lamme M，et al.Increasing evidence for the safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy［J］.Retina，2023，43（3）：379-388.
［48］	Van-Dijk EHC，Van-Rijssen TJ，Subhi Y，et al.Photodynamic therapy for chorioretinal diseases：A practical approach［J］.Ophthalmol Ther，2020，9（2）：329-342.
［49］	Iĝk MU， Deĝirmenci MFK， Saĝllk A. Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy［J］.Int JOphthalmol，2020，13（9）：1404-1410.
［50］	Mohabati D，Boon CJF，Yzer S.Risk of recurrence and transition to chronic disease in acute central serous chorioretinopathy［J］.Clin Ophthalmol，2020，14：1165-1175.
［51］	Zhao MW，Zhang F，Chen YX，et al.A 50% vs 30% dose of verteporfin（photodynamic therapy）for acute central serous chorioretinopathy：One-year results of a randomized clinical trial［J］.JAMA Ophthalmol，2015，133（3）：333-340.
［52］	Van-Rijssen TJ，Van-Dijk EH，Dijkman G，et al.Reply to comment on：Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy［J］.Am JOphthalmol，2021，222：397-398.
［53］	Bandello F， Lanzetta P， Furlan F， et al. Non visible subthreshold micropulse diode laser treatment of idiopathic central serous chorioretinopathy.A pilot study［J］.Invest Ophthalmol Vis Sci，2003，44（13）：4858.
［54］	赵会孟，张有花，解孝锋.微脉冲激光在眼科疾病中的应用进展［J］.中国中医眼科杂志，2023，33（2）：170-174.
［55］	Ambiya V，Goud A，Mathai A，et al.Microsecond yellow laser for subfoveal leaks in central serous chorioretinopathy［J］.Clin Ophthalmol，2016，10：1513-1519.
［56］	Prasuhn M，Miura Y，Tura A，et al.Influence of retinal microsecond pulse laser treatment in central serous chorioretinopathy：A short-term optical coherence tomography angiography study［J］.Preprints，2021，10（11）：2418.
［57］	吴妍，陈放，李喆.微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变的短期效果观察［J］.中华眼外伤职业眼病杂志，2022，44（12）：881-888.
［58］	Arsan A，Kanar HS，Sonmez A.Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser（577-nm）treatment for chronic central serous chorioretinopathy：long-term follow-up［J］.Eye，2018，32（4）：726-733.

Please choose a citation manager

Content to export